The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies neutralize the intended SARS-CoV-2 variant.

Scientists have conducted breakthrough research that could lead to a universal cancer vaccine, revolutionizing how the disease is treated.

This is the time of year when updated boosters for COVID-19 are typically available. But this year has been anything but typical.

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

A Florida pharmacy licensing board on Tuesday made clear that prescriptions aren’t necessary for patients who want to get ...

The protein-based vaccine now covers the LP.8.1 variant and can be given to adolescents aged 12 years or older who previously ...

People are still debating whether the mRNA from COVID-19 vaccines remains in the body longer than it should. Some say it ...

Moderna's 2025-2026 mNEXSPIKE showed strong immune response and safety in Phase 4 trials, reinforcing FDA approval for the LP.8.1-targeting formula.

President Donald Trump used his platform to promote unproven and in some cases discredited ties between Tylenol, vaccines and ...

Moderna has early in-human data showing its next-generation COVID-19 vaccine, mNEXSPIKE, has the potential to offer strong immune protection against the latest rapidly spreading SARS-CoV-2 virus.

Moderna (MRNA) stock is in focus as its updated mNEXSPIKE COVID vaccine boosts antibodies 15-fold on average against the new ...

Moderna (MRNA) announced preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, which targets the LP.8.1 variant of SARS-CoV-2 to ...